OnKure Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $15.3 million, a slight decrease from the $15.4 million loss recorded in the same period of the previous year. For the six months ending June 30, 2026, the company reported a net loss of $30.5 million, compared to a loss of $31.3 million for the first half of 2025. The company’s total operating expenses for the second quarter were $16.9 million, up from $16.3 million year-over-year, primarily driven by increased general and administrative costs.
The company’s cash and cash equivalents significantly increased to $166.5 million as of June 30, 2026, compared to $59.1 million at the end of 2025. This increase was largely attributed to the completion of a private placement in March 2026, which raised approximately $150 million before expenses. The company’s accumulated deficit now stands at $244.7 million, reflecting its ongoing investment in research and development without generating revenue from product sales.
OnKure continues to focus on advancing its clinical programs, particularly its next-generation PI3Kα pan-mutant programs, OKI-345 and OKI-355, which target specific mutations in cancer and vascular anomalies. The company plans to submit Investigational New Drug applications for these candidates in the first half of 2027. Research and development expenses for the second quarter remained stable at $12.6 million, with a slight increase in clinical trial costs offset by a decrease in outsourced preclinical research expenses.
The company’s workforce has expanded, with a total of 49.9 million shares outstanding as of June 30, 2026, reflecting the issuance of shares in connection with the private placement. OnKure's management anticipates continued operating losses as it progresses through clinical trials and regulatory processes. The company has indicated that it will require additional capital to fund its operations and development activities, which may involve further equity or debt financing. The outlook remains cautious, with management acknowledging the potential impact of macroeconomic factors on its operations and funding strategies.
About OnKure Therapeutics, Inc.
OnKure Therapeutics is a biopharmaceutical company specializing in precision cancer medicines. Its core focus is developing highly selective small molecule inhibitors targeting mutated oncogenes, particularly PI3Kα mutations in breast and other cancers. The company’s pipeline includes mutation-specific therapies designed to improve efficacy and safety, with a strategic emphasis on targeted, mutation-driven treatments for underserved patient populations in oncology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov